Trial Profile

A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interleukin-15 (Primary) ; Spartalizumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Admune Therapeutics; Novartis; Novartis Pharmaceuticals

Most Recent Events

01 Mar 2023 Status changed from completed to discontinued due to business decision.
22 Mar 2022 Status changed from active, no longer recruiting to completed.
28 Jan 2022 Planned End Date changed from 24 Jan 2022 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com